Sponsor
Boehringer Ingelheim
Clinical research sponsor
Clinical trials
60 shownA Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813 · lead sponsor · 2026-09-02
RECRUITINGA Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or ObesityNCT07754474 · lead sponsor · 2026-09-01
RECRUITINGA Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · lead sponsor · 2026-08-24
RECRUITINGBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · lead sponsor · 2026-06-04
RECRUITINGBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · lead sponsor · 2026-01-16
RECRUITINGDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · lead sponsor · 2025-11-07
RECRUITINGEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · lead sponsor · 2025-07-22
RECRUITINGConnective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)NCT05819385 · lead sponsor · 2025-06-18
RECRUITINGA Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · lead sponsor · 2025-05-20
RECRUITINGA Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerNCT05963867 · lead sponsor · 2024-08-06
RECRUITINGBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadNCT06324357 · lead sponsor · 2024-06-28
RECRUITINGA Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288 · lead sponsor · 2024-06-17
RECRUITINGDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersNCT05882058 · lead sponsor · 2023-10-13
RECRUITINGReal-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection FractionNCT07044700 · lead sponsor · 2028-01-31
NOT_YET_RECRUITINGReal-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection FractionNCT07047508 · lead sponsor · 2028-01-31
NOT_YET_RECRUITINGSYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · lead sponsor · 2026-11-07
NOT_YET_RECRUITINGSYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050 · lead sponsor · 2026-10-31
NOT_YET_RECRUITINGELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063 · lead sponsor · 2026-10-23
NOT_YET_RECRUITINGDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersNCT07707895 · lead sponsor · 2026-10-19
NOT_YET_RECRUITINGA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)NCT07843940 · lead sponsor · 2026-10-05
NOT_YET_RECRUITINGA Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or OverweightNCT07693231 · lead sponsor · 2026-07-21
ACTIVE_NOT_RECRUITINGA Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122 · lead sponsor · 2026-06-30
ACTIVE_NOT_RECRUITINGA Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348 · lead sponsor · 2026-03-11
ACTIVE_NOT_RECRUITINGA Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 · lead sponsor · 2026-03-03
COMPLETEDReal-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United StatesNCT07342309 · lead sponsor · 2025-09-30
ACTIVE_NOT_RECRUITINGA Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 · lead sponsor · 2025-03-26
ACTIVE_NOT_RECRUITINGA Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaNCT06791122 · lead sponsor · 2025-01-23
COMPLETEDA Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 · lead sponsor · 2024-11-01
ACTIVE_NOT_RECRUITINGA Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 · lead sponsor · 2024-10-01
COMPLETEDA Study to Test Different Doses of BI 1569912 in People With DepressionNCT06558344 · lead sponsor · 2024-10-01
COMPLETEDA Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135 · lead sponsor · 2024-08-12
COMPLETEDA Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or ObesityNCT06352437 · lead sponsor · 2024-06-10
COMPLETEDA Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302 · lead sponsor · 2024-05-15
ACTIVE_NOT_RECRUITINGA Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityNCT06352424 · lead sponsor · 2024-04-30
COMPLETEDA Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 · lead sponsor · 2024-04-02
COMPLETEDA Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · lead sponsor · 2024-03-27
COMPLETEDA Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467 · lead sponsor · 2024-03-13
COMPLETEDA Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6NCT06091930 · lead sponsor · 2024-02-16
TERMINATEDDAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerNCT06077500 · lead sponsor · 2024-02-14
ACTIVE_NOT_RECRUITINGDAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyNCT05990738 · lead sponsor · 2024-02-14
ACTIVE_NOT_RECRUITINGBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · lead sponsor · 2024-02-09
ACTIVE_NOT_RECRUITINGA Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 · lead sponsor · 2024-02-06
COMPLETEDA Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseNCT06176365 · lead sponsor · 2024-01-16
COMPLETEDA Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the BellyNCT06082843 · lead sponsor · 2024-01-03
TERMINATEDA Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodNCT05896384 · lead sponsor · 2023-12-21
COMPLETEDA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · lead sponsor · 2023-11-27
COMPLETEDDeveloping a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk FactorsNCT05855109 · lead sponsor · 2023-11-27
COMPLETEDA Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 · lead sponsor · 2023-11-25
COMPLETEDA Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · lead sponsor · 2023-11-20
COMPLETEDNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in FranceNCT05882071 · lead sponsor · 2023-11-15
ACTIVE_NOT_RECRUITINGA Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver CirrhosisNCT05741372 · lead sponsor · 2023-09-07
COMPLETEDA Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver DiseaseNCT05970640 · lead sponsor · 2023-08-14
COMPLETEDA Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3NCT05879978 · lead sponsor · 2023-06-27
ACTIVE_NOT_RECRUITINGA Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906NCT05751226 · lead sponsor · 2023-04-11
COMPLETEDA Study to Compare Tissue and Liquid Biopsies in People With Different Types of CancerNCT05708599 · lead sponsor · 2023-03-01
ACTIVE_NOT_RECRUITINGEmp-Activity: Empagliflozin Functional CapacityNCT05350202 · lead sponsor · 2022-12-18
COMPLETEDBrightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderNCT05512377 · lead sponsor · 2022-12-13
COMPLETEDEffectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in TaiwanNCT05402020 · lead sponsor · 2022-09-30
COMPLETEDSafety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) DataNCT05393245 · lead sponsor · 2022-09-30
COMPLETEDEvaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney DiseaseNCT05465317 · lead sponsor · 2022-08-08
COMPLETEDSponsor roles
lead sponsor868
collaborator189
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.